Sarepta Therapeutics announced that Michael Severino, previously chief executive of Tessera Therapeutics, will assume the role of chief executive officer effective the day after the company’s announcement. The appointment replaces Doug Ingram, who had indicated earlier in 2026 that he planned to retire after leading Sarepta for nearly a decade. The public report of the hire appeared as a STAT News piece designated as a STAT+ exclusive; portions of the coverage were behind a subscriber paywall.
Doug Ingram led Sarepta for almost ten years. During his leadership the company secured regulatory approvals for three therapies targeting Duchenne muscular dystrophy. Those approvals represent a significant commercial and development milestone for a company focused on therapies for a rare neuromuscular disease.
At the same time, the company has contended with persistent questions about the efficacy of some of its Duchenne products. The STAT report references ongoing debate and scrutiny over how effective those approved therapies are in clinical practice and in the regulatory record.
Sarepta’s gene therapy program has faced regulatory attention tied to safety concerns. The STAT report notes that regulators have raised issues following an event in which a patient death was associated with a Sarepta gene therapy program. The reporting indicates that this has led to increased oversight of the company’s gene-therapy activities.
The article does not provide detailed timelines, regulatory filings, or the specific products involved beyond noting that gene therapy safety prompted scrutiny. It also does not report investigational or corrective actions that regulators may have required, nor does it provide internal company responses beyond the leadership change announcement.
The public coverage states that Sarepta’s share price has fallen significantly from the level it held at the beginning of 2025. This decline is presented as context for the leadership transition, reflecting investor concern tied to efficacy questions, safety scrutiny, and competitive pressures in the Duchenne field.
The STAT piece does not quantify the share-price decline in percentage or dollar terms in the publicly accessible portion, nor does it include contemporaneous market data, analyst commentary, or explicit linkage between specific events and stock movements beyond the general observation that the share price has “tanked.”
Because the STAT article is a STAT+ exclusive with much content behind a paywall, several operational and transactional details were not available in the public excerpt. Specifically, the publicly available portion did not report:
These omissions reflect the limitations of the public excerpt of the STAT report rather than an absence of such information in company filings or more detailed coverage. Readers seeking comprehensive specifics about Severino’s mandate, the company’s regulatory interactions, or financial metrics will need to consult the full STAT+ article, company press releases, SEC filings, or subsequent reporting.
From the facts presented in the STAT excerpt, the leadership change replaces a long-tenured CEO who delivered multiple Duchenne approvals with an executive experienced at another biotechnology company. The announcement occurs against a backdrop of regulatory safety scrutiny, continued debate about therapeutic efficacy in the company’s core disease area, and a materially weakened market valuation.
The public account does not identify Severino’s immediate tactical plans or whether he will alter clinical development, regulatory strategy, or commercial positioning. It also does not report how investors, patient groups, or regulators reacted to the appointment.
For clinicians, researchers, and investors tracking Sarepta, the key reported facts are the CEO succession to Michael Severino, the historical context of approvals under Doug Ingram, and the ongoing regulatory and efficacy controversies surrounding Sarepta’s Duchenne and gene-therapy programs. Additional, actionable details were not reported in the public excerpt and will require access to the full STAT+ story or primary company disclosures for confirmation.